Literature DB >> 8483621

How common is whooping cough in a nonvaccinating country?

J Isacson1, B Trollfors, J Taranger, G Zackrisson, T Lagergård.   

Abstract

In Sweden general vaccination with a whole cell pertussis vaccine was recommended from 1953. In 1979 the recommendation was withdrawn because the Swedish-made vaccine had become ineffective. In order to determine the incidence of the disease in a nonvaccinating country, 400 children born in 1980 were randomly selected from the population register of Göteborg, Sweden. The parents of the children were interviewed in 1990, when the children were 10 years old. The parents of 377 children could be reached, and of those 372 were not vaccinated against pertussis. Of the nonvaccinated children 61% had experienced clinically typical whooping cough; 195 (119 with and 76 without a history of whooping cough) agreed to donate a serum sample for determination of antibodies against pertussis toxin, filamentous hemagglutinin and pertactin. Of the children with a history of whooping cough, 91% had antibodies against pertussis toxin, as had 64% of the children without a history of disease. All but 3 children had antibodies against filamentous hemagglutinin and all 195 children had antibodies against pertactin. The antibody titers against the 2 last mentioned proteins did not differ between children with and without a history of whooping cough or between children with and without antibodies against pertussis toxin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8483621     DOI: 10.1097/00006454-199304000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Update of epidemiology, diagnosis, and treatment of pertussis.

Authors:  J E Hoppe
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

Review 2.  Which strategy for pertussis vaccination today?

Authors:  Dorota Z Girard
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

3.  Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella parapertussis infections.

Authors:  L Lind-Brandberg; C Welinder-Olsson; T Lagergård; J Taranger; B Trollfors; G Zackrisson
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

4.  Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.

Authors:  Roland Sänger; Ulrich Behre; Karl-Heinz Krause; Hans-Peter Loch; Peter Soemantri; Dietmar Herrmann; Eugenie Schmitz-Hauss; Joanne Wolter; Bernard Hoet
Journal:  Eur J Pediatr       Date:  2007-01-18       Impact factor: 3.183

Review 5.  A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.

Authors:  S S Patel; A J Wagstaff
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

6.  Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data.

Authors:  H E de Melker; J F Schellekens; S E Neppelenbroek; F R Mooi; H C Rümke; M A Conyn-van Spaendonck
Journal:  Emerg Infect Dis       Date:  2000 Jul-Aug       Impact factor: 6.883

7.  Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status.

Authors:  E Torbicka; T Lagergård; B Trollfors
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.